Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 13/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 13/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 13/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 13/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 13/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 9/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 8/20 | 1.00 |
| ▸ | GABRP | O00591 | 6/20 | 1.00 |
| ▸ | GABRD | O14764 | 6/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | GABRE | P78334 | 6/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 6/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672619 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30274389 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Beta-Ccm SCHEMBL15648382 | 0.95 | GABRA1 (0.91) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7379654 | 0.92 | GABRA1 (0.84) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2348263 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2214572 | 0.88 | ALDH1A1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29766941 | 0.88 | ALDH1A1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31163651 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10740909 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7384200 | 0.87 | ALDH1A1 (0.93) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2024-03-14 | — | — | US | claimed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | claimed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| CN-111349096-A | Indole compound and preparation method and application thereof | 石河子大学 | 2020-06-30 | — | — | CN | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-20150094351-A1 | COMPOSITION FOR TOPICAL USE | THESAN PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | US | claimed |
| US-20100324109-A1 | Composition for Topical Use | THESAN PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | claimed |
| US-20100009997-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIARTY DISORDER WITH A BH4 DERIVATIVE PRODRUG | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-01-14 | — | — | US | claimed |
| WO-2008089148-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIATRY DISORDER WITH A BH4 DERIVATIVE PRODRUG | BIOMARIN PHARMACEUTICAL INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-0161575-B1 | B-CARBOLINE-3-CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THE SAME AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-06-13 | — | — | EP | claimed |
| EP-0030254-B1 | BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-10-31 | — | — | EP | claimed |
| EP-0030254-A1 | Beta-carbolin-3-carboxylic acid derivatives, pharmaceutical compositions containing them and their therapeutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | claimed |
| JP-57004987-A | — | — | None | — | — | JP | disclosed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| EP-0054507-A2 | 3-Substituted beta-carbolines, process for their production and compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-06-23 | — | — | EP | disclosed |
| JP-S574987-A | PYRIDOINDOLECARBOXYLIC ACID DERIVATIVE AND ITS PREPARATION | SANKYO CO LTD | 1982-01-11 | — | — | JP | disclosed |
| EP-0030254-A1 | Beta-carbolin-3-carboxylic acid derivatives, pharmaceutical compositions containing them and their therapeutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | GABRA1 3396/4885GABRG2 3469/4885GABRB3 2510/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | GABRA1 1411/4885GABRG2 1612/4885GABRB3 1220/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | GABRA1 1444/4885GABRG2 1697/4885GABRB3 898/4885 |
| US-20100009997-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIARTY DISORDER WITH A BH4 DERIVATIVE PRODRUG | PAH, HSD17B4, UGT1A4 | GABRA1 1783/4885GABRG2 1826/4885GABRB3 1532/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | GABRA1 1444/4885GABRG2 1697/4885GABRB3 898/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GABRA1 943/4885GABRG2 1201/4885GABRB3 554/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GABRA1 1411/4885GABRG2 1612/4885GABRB3 1220/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | GABRA1 2815/4885GABRG2 2851/4885GABRB3 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.